Anastasia A. Dmitrieva

Anastasia A. Dmitrieva

Auto-generated profile, based on publicly available information

Anastasia A. Dmitrieva

Joint-Stock Company “R-Pharm

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
VKV. M. Kosman
V. M. Kosman
MKM. V. Karlina
M. V. Karlina
TBT. N. Barybina
T. N. Barybina
NFN. M. Faustova
N. M. Faustova
AMA. A. Matichin
A. A. Matichin
VIV. G. Ignatiev
V. G. Ignatiev
Background. Pembrolizumab belongs to a fundamentally new class of antitumor agents with biological source – monoclonal antibodies. when creating generic biological medicinal products, it is necessary to assess the comparability of the pharmacokinetics of the developed drug and the original (reference) drug product in relevant animal species.Aim. To compare the pharmacokinetics of two drugs with INN pembrolizumab, concentrate for solution for infusion, administered once intravenously to Macaca fascicularis.Materials and methods. Biosimilar RPH-075 (INN pembrolizumab, JSC R-Pharm, Russia) and reference drug Keytruda® (INN pembrolizumab, MSD International GmbH) were administered once intravenously to male monkeys (2 groups of 4 males each) at a dose of 30 mg/kg. Macaque blood samples were collected for analysis before administration and at 1, 2, 4, 8, 24, 48, 72, 144, 312, 480, 648, 984, 1320 h after administration. Plasma concentrations of the active ingredient were determined by bridging ELISA using commercially available antibodies, followed by calculation of the main pharmacokinetic parameters (Cmax, AUC, MRT, Vss, T1/2, Cl).Results. Using antibodies more available than commercial reagent kits, the pembrolizumab assay method recommended by the antibody manufacturer has been replicated. The method has been validated and applied to the analysis of biosamples obtained in the preclinical study. There was no effect of the test drug and the reference drug upon single intravenous administration to monkeys condition and animals body weigh; drugs were found to have comparable pharmacokinetic profiles.Conclusion. The creation of a biosimilar drug in the Russian Federation will improve the treatment of patients with cancer, reduce the cost of treatment and increase the number of patients receiving high-quality medical care.

8 December 2022 in Biological Products. Prevention, Diagnosis, Treatment
Verified
Journal Article
Open access
PDF file
ESE. V. Shipaeva
E. V. Shipaeva
OFO. V. Filon
O. V. Filon
AZA. V. Zintchenko
A. V. Zintchenko
GSG. A. Shipunov
G. A. Shipunov
ADA. A. Dmitrieva
A. A. Dmitrieva
ЯЛЯ. В. Лавровский
Я. В. Лавровский
Finding effective and safe medicines to fight SARS-CoV-2 infection is an urgent task. RPH-137 is an original trap fusion protein against SARS-CoV-2 virus. It comprises the angiotensin-converting enzyme type 2 extracellular domain and the human IgG1 Fc fragment.The aim of the study was to carry out a preclinical evaluation of the efficacy of RPH-137 and molnupiravir against SARS-CoV-2 infection.Materials and methods: the authors analysed RPH-137 expressed in a stable CHO cell line and molnupiravir used as an active pharmaceutical ingredient. Drug-mediated inhibition of virus-induced cytotoxicity was assessed in Vero cell culture. In vivo efficacy assessments were performed in Syrian hamsters. The animals were infected intranasally with SARS-CoV-2 (PIK35 clinical isolate) in the dose of 5 log TCID50. The authors evaluated body weight measurements, lung–body weight ratios, and lung histopathology findings and determined viral RNA levels in oropharyngeal swabs by RT-PCR using the amplification cycle threshold (Ct). The statistical analyses involved one- and two-way ANOVA, Student's t-test, and Mann–Whitney test.Results: RPH-137 and molnupiravir inhibited the cytopathic effect of SARS-CoV-2 in Vero cells; the EC50 values of RPH-137 amounted to 4.69 μg/mL (21.3 nM) and 16.24 μg/mL (73.8 nM) for 50 TCID50 and 200 TCID50, respectively, whereas the EC50 values of molnupiravir were 0.63 μg/mL (1900 nM) for both doses. Intramuscular RPH-137 (30 and 80 mg/kg) had no effect on the infection process in Syrian hamsters. The comparison with the challenge control group showed that intraperitoneal RPH-137 (100 mg/kg) had statistically significant effects on a number of parameters, including a 27% reduction in inflammation and a 30% reduction in the total lesion area of the lungs by Day 7. Intragastric molnupiravir (300 mg/kg twice daily) significantly inhibited SARS-CoV-2 infection.Conclusions: both RPH-137 and molnupiravir inhibited the cytopathic effect of SARS-CoV-2 in Vero cells. In Syrian hamsters, molnupiravir demonstrated a more pronounced inhibition of SARS-CoV-2 infection than RPH-137. However, RPH-137 had statistically significant effects on a range of parameters. This offers additional perspectives for further research.

21 December 2024 in Russian Journal of Oncology
Verified
Journal Article
Closed access
PDF file
APAnna I. Podolyakina
Anna I. Podolyakina
ADAnastasia A. Dmitrieva
Anastasia A. Dmitrieva
VPVictoria A. Postnikova
Victoria A. Postnikova
AKAnastasia A. Konstantinova
Anastasia A. Konstantinova
APAnna V. Petkova
Anna V. Petkova
ИГИгнатьев Василий Геннадьевич
Игнатьев Василий Геннадьевич
BACKGROUND: Developing biosimilar monoclonal antibodies for treating malignant diseases is a critical task. RPH-051 (pertuzumab) is a biosimilar drug, a recombinant humanized monoclonal antibody targeting type 2 human epidermal growth factor receptors. At the stage of non-clinical development, studies of pharmacokinetics of biosimilar vs. original drug product in a relevant animal species, provide important information on the comparability of drugs. AIM: To evaluate the pharmacokinetics of the biosimilar product RPH-051 in comparison with the original drug after a single intravenous injection in a cynomolgus monkey model. MATERIALS AND METHODS: The study was conducted in 8 cynomolgus monkeys (Macaca fascicularis) divided into 2 groups, each including 2 females and 2 males. The first group received the biosimilar RPH-051 (international nonproprietary name is pertuzumab, AO R-Pharm, Russia), the second group was treated with the comparator Perjeta® (international nonproprietary name is pertuzumab). The drugs were administered as a single intravenous dose of 50 mg/kg. Blood samples were collected before dosing, then at 1 min, 1, 2, 4, 8, 24 h, and on days 3, 7, 10, 14, 21 and 28 post-dosing. Quantitative analysis of pertuzumab serum levels was performed using enzyme-linked immunosorbent assay (ELISA) with spectrophotometric detection in the visible range of the spectrum. RESULTS: The method of quantitative assessment of serum level of pertuzumab using (ELISA) in cynomolgus monkeys was developed. The method was validated against the following parameters: selectivity, minimum required dilution, lower limit of quantification, calibration range, accuracy and precision (within the analytical run and between runs), specificity, linearity (possibility) of sample dilution, parallelism, and stability of the analyte in serum. Comparability of the drugs in the main pharmacokinetic parameters was established. The mean Cmax and AUClast values of RPH-051 and of the comparator were 1684.34 and 1405.34 μg/mL (Cmax); 265,282.18 and 280,168.92 (μg/mL)×h (AUClast), respectively. CONCLUSION: Comparability between the pharmacokinetic profiles of the biosimilar RPH-051 and the originator’s drug was demonstrated. In the course of the study, no adverse clinical events, animal body weight changes, or injection site reactions associated with the tested drugs were observed.

30 April 2026 in Russian Journal of Biotherapy
Verified
Journal Article
Open access
PDF file
VCValeriia S. Chernyshenko
Valeriia S. Chernyshenko
NFNatalia M. Faustova
Natalia M. Faustova
VKVera M. Kosman
Vera M. Kosman
MKMarina V. Karlina
Marina V. Karlina
ARAnna Yu. Romanenko
Anna Yu. Romanenko
VIVasiliy G. Ignatiev
Vasiliy G. Ignatiev
Background. To ensure the safety and effectiveness of biological drugs, it is critically important to evaluate their immunogenicity. The most commonly used enzyme-linked immunosorbent assay (ELISA) has a number of limitations, so it is important to understand the possibilities of alternative approaches, for example, the biolayer interferometry (BSI) method. Aim. Development, validation and comparison of two methods for screening assay in the context of assessing the immunogenicity of biological drugs based on monoclonal antibodies using the example of pembrolizumab with multiple intravenous administration to Macaca fascicularis. Materials and methods. Immunogenicity was evaluated as part of a comparative study of toxicity and local tolerance of two drugs with International Nonproprietary Name pembrolizumab following repeated administration. Macaca fascicularis (3 groups of 3 males and 3 females in each) on days 1, 8, 15 and 22 of the experiment received intravenously a control substance (buffer solution), test drug (RPH-075, JSC R-Pharm, Russia) and reference drug (Keytruda®, MSD International GmbH, Ireland) at a dose 30 mg/kg. Serum samples, were collected pre-dose and on study days 15, 22, 29, and were tested for assessment of binding antibodies to pembrolizumab using two methods, bridging ELISA and BSI. Results. During the development and testing of methods for binding antibodies (BAb) to pembrolizumab quantification in monkey’s blood serum of by the bridge ELISA and BSI assays, it was revealed that the bridge ELISA has greater sensitivity (12.3 and 419.7 ng/mL, respectively). Determination of BAb level to pembrolizumab by ELISA revealed immunogenicity in 4 out of 12 animals; when analyzing samples by BSI, an increasing of BAb concentration was detected in only one animal. Conclusion. Bridging ELISA is more sensitive than BSI making it the preferred method for assessing of drugs with unknown or suspected low immunogenicity.